{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of 95% Confidence interval were not estimable at the time of the final analysis due to an insufficient number of participants with events within the length of follow-up in assessing the number of events.","groupId":"OG000","lowerLimit":"4.2","upperLimit":"NA","value":"NA"},{"comment":"Upper limit of 95% Confidence interval was not estimable at the time of the final analysis due to an insufficient number of participants with events within the length of follow-up in assessing the number of events.","groupId":"OG001","lowerLimit":"4.9","upperLimit":"NA","value":"22.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"DoR is defined as the time from first documented evidence or PR or better until progressive disease per IMWG or death due to progressive disease among participants who achieve confirmed partial response or better.","dispersionType":"95% Confidence Interval","groups":[{"description":"In CE Phase, Participants with RRMM received 0.95 mg/ kg belantamab mafodotin IV infusion as powder for solution once every 3 weeks (Q3W), infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 100 mg nirogacestat BID on day 1, 4, 8 and 15 of 21-day cycles. Treatment was administered until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG000","title":"CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat"},{"description":"In CE Phase, Participants with RRMM received 2.5 mg/ kg belantamab mafodotin IV infusion as powder for solution Q3W, infused over 30- 60 minutes on day 1 of 21-day cycles until disease progression, intolerable toxicity, informed consent withdrawal, the end of the sub-study or death.","id":"OG001","title":"CE Phase: 2.5mg/kg Belantamab Mafodotin Q3W"}],"paramType":"MEDIAN","populationDescription":"Safety Population. Only those participants with a confirmed PR or better as the best overall response (i.e., PR, VGPR, CR, and sCR) were assessed for this endpoint.","reportingStatus":"POSTED","timeFrame":"Up to approximately 253 weeks","title":"CE Phase: Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}